AR124384A1 - Parapoxvirus modificado que tiene inmunogenicidad aumentada - Google Patents

Parapoxvirus modificado que tiene inmunogenicidad aumentada

Info

Publication number
AR124384A1
AR124384A1 ARP210103524A ARP210103524A AR124384A1 AR 124384 A1 AR124384 A1 AR 124384A1 AR P210103524 A ARP210103524 A AR P210103524A AR P210103524 A ARP210103524 A AR P210103524A AR 124384 A1 AR124384 A1 AR 124384A1
Authority
AR
Argentina
Prior art keywords
parapoxvirus
modified parapoxvirus
increased immunogenicity
modified
vector
Prior art date
Application number
ARP210103524A
Other languages
English (en)
Inventor
Amann Ralf Dr
Ferdinand Salomon
Original Assignee
Univ Tuebingen Medizinische Fakultaet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tuebingen Medizinische Fakultaet filed Critical Univ Tuebingen Medizinische Fakultaet
Publication of AR124384A1 publication Critical patent/AR124384A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24241—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a un Parapoxvirus modificado, preferiblemente un vector Parapoxvirus, que tiene una inmunogenicidad aumentada, una célula biológica que contiene dicho Parapoxvirus modificado, una composición farmacéutica, preferiblemente una vacuna, que contiene dicho vector Parapoxvirus modificado y/o dicha célula, y un nuevo uso de dicho Parapoxvirus modificado. Reivindicación 1: Un Parapoxvirus modificado que comprende al menos una mutación funcional en el marco de lectura abierto (ORF) viral que codifica un “inhibidor de NF-kB”, en el que dicho virus comprende una inmunogenicidad aumentada en comparación con el mismo vector sin dicha mutación funcional.
ARP210103524A 2020-12-21 2021-12-16 Parapoxvirus modificado que tiene inmunogenicidad aumentada AR124384A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20216198.0A EP4014991A1 (en) 2020-12-21 2020-12-21 Modified parapoxvirus having increased immunogenicity

Publications (1)

Publication Number Publication Date
AR124384A1 true AR124384A1 (es) 2023-03-22

Family

ID=73856481

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210103524A AR124384A1 (es) 2020-12-21 2021-12-16 Parapoxvirus modificado que tiene inmunogenicidad aumentada

Country Status (13)

Country Link
EP (2) EP4014991A1 (es)
JP (1) JP2024500167A (es)
KR (1) KR20230122630A (es)
CN (1) CN117015609A (es)
AR (1) AR124384A1 (es)
AU (1) AU2021408377A1 (es)
CA (1) CA3202003A1 (es)
CL (1) CL2023001816A1 (es)
CO (1) CO2023008292A2 (es)
IL (2) IL303876A (es)
MX (1) MX2023007444A (es)
TW (1) TW202239428A (es)
WO (1) WO2022136033A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023233007A1 (en) * 2022-06-02 2023-12-07 Eberhard Karls Universität Tübingen Medizinische Fakultät Sars-cov-2 vaccines and uses thereof

Also Published As

Publication number Publication date
EP4014991A1 (en) 2022-06-22
CL2023001816A1 (es) 2024-01-12
WO2022136033A1 (en) 2022-06-30
JP2024500167A (ja) 2024-01-04
EP4153231A1 (en) 2023-03-29
IL303876A (en) 2023-08-01
CO2023008292A2 (es) 2023-07-21
MX2023007444A (es) 2023-07-03
CN117015609A (zh) 2023-11-07
AU2021408377A1 (en) 2023-06-29
KR20230122630A (ko) 2023-08-22
CA3202003A1 (en) 2022-06-30
TW202239428A (zh) 2022-10-16
IL303878A (en) 2023-08-01

Similar Documents

Publication Publication Date Title
AR053913A1 (es) Cepa atenuada de dengue serotipo 1
BRPI0208301B8 (pt) ácido nucléico isolado, e, composição
ATE465750T1 (de) Verwendung eines replikationdefizienten pockenvirusvektors zur erhöhung der cd4+ t-zell- immunantwort gegen antigen
ECSP045300A (es) Antígenos virales
AR053914A1 (es) Cepa atenuada del dengue serotipo 2
BRPI0309631A8 (pt) vacina tetravalente da dengue contendo uma trivial deleção de 30 nucleotídeos na utr-31' dos tipos de dengue 1,2,3 e 4, ou de vírus antigênicos quiméricos da dengue 1,2,3 e 4
CY1112140T1 (el) Ανασυνδυασμενοι ιοι γριππης για εμβολια και γονιδιακη θεραπεια
ATE552846T1 (de) Verbesserter grippeimpfstoff
CY1110525T1 (el) Βελτιστοποιημενη εκφραση της hpv 45 li σε ζυμη
DE60121136D1 (de) Proteasom-influenzavirus-impfstoffzusammensetzung
Kim et al. Comprehensive early and lasting loss of memory CD8 T cells and functional memory during acute and persistent viral infections
AR065076A1 (es) Vacuna contra el papilomavirus
PE20121685A1 (es) Antigeno ndv recombinante y usos del mismo
CO6300963A2 (es) Una vacuna contra la malaria que comprende p. falciparum y p. vivax
EA201500910A1 (ru) Вакцины против гриппа со сниженным количеством сквалена
AR124384A1 (es) Parapoxvirus modificado que tiene inmunogenicidad aumentada
DK1425404T3 (da) Vaccinia-MVA-E3L-mutanter og anvendelse deraf
BR0207988A (pt) Cepas atenuadas vivas de vìrus de prrs
BR0317544A (pt) Uso de uma composição que compreende vlps de hpv 16 e hpv 18, e, métodos para induzir uma resposta imune contra um ou mais do grupo de tipos de hpv oncogênicos, para prevenir infecção e/ou doença causada por um ou mais do grupo de tipos de hpv oncogênicos, para prevenir a infecção de uma população de pacientes por um ou mais tipos de hpv, uso de uma mistura de vlps de hpv 16 e hpv18, e, composição de vacina
WO2004016586A3 (en) Compositions and methods related to flavivirus envelope protein domain iii antigens
AR057225A1 (es) Vacunas marcadas contra el virus de la diarrea virica bovina
AR067439A1 (es) Virus quimericos antigenicos de virus de encefalitis de st. louis/virus dengue tipo 4
CO2023008047A2 (es) Parapoxvirus modificado que tiene inmunogenicidad incrementada
NZ603854A (en) West nile virus vaccine
Siddharta et al. Virucidal activity of WHO-recommended formulations against enveloped viruses including Zika, Ebola and emerging Coronaviruses